Ipsen announced the voluntary withdrawal of Tazverik (tazemetostat) from the U.S. market and the suspension of ongoing studies after an independent monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial. The company said it is discontinuing development activities and will ensure patients are transitioned to standard‑of‑care treatments. Tazverik was previously approved for epithelioid sarcoma and follicular lymphoma under accelerated pathways. The withdrawal follows safety signals that Ipsen concluded may outweigh benefit in certain indications. The company noted the decision will not materially change its near‑term financial guidance but will require portfolio and regulatory reassessments. Regulatory and clinical implications: the move underscores post‑approval surveillance importance and may prompt review of other agents with similar mechanisms. Sponsors running confirmatory trials should expect heightened scrutiny of secondary malignancy signals in long‑term safety data.